« àÁ×èÍ: 07/05/22 àÇÅÒ 10:30:38 » |
|
਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì (JW Therapeutics) (HKEX: 2126) ºÃÔÉÑ·à·¤â¹âÅÂÕªÕÇÀÒ¾ÅéÓÊÁÑ·ÕèÁØ觾Ѳ¹Ò ¼ÅÔµ áÅШѴ¨Ó˹èÒÂà·¤â¹âÅÂÕ¡ÒúӺѴ´éÇÂà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ »ÃСÒÈàÃÔèÁ¡Ò÷´Åͧ·Ò§¤ÅÔ¹Ô¡à¿Ê˹Öè§ à¾×èÍÈÖ¡ÉÒ»ÃÐÊÔ·¸ÔÀÒ¾¢Í§ÂÒ JWATM204 ã¹¼Ùé»èÇÂÁÐàÃç§à«ÅÅìµÑº (HCC) ÃÐÂÐÅØ¡ÅÒÁ âäÁÐàÃ秵Ѻ (PLC) ËÃ×Í·ÕèàÃÕ¡¡Ñ¹ÇèÒâäÁÐàÃ秢ͧà«ÅÅìµÑº à»ç¹âäÃéÒ·ҧÃкº¡ÃÐà¾ÒÐáÅÐÅÓäÊé·Õ辺ä´éºèÍÂà»ç¹Íѹ´Ñºµé¹ æ ·ÑèÇâÅ¡ â´Â»ÃÐÁÒ³ 85%-90% ¢Í§ÁÐàÃ秵Ѻà»ç¹ÁÐàÃç§à«ÅÅìµÑº (HCC)[1] ¢³Ð·Õè¡ÒÃÊÓÃǨâ¤Ã§¡ÒÃâ¡Åâºá¤¹ (GLOBOCAN) àÁ×èÍ»Õ 2563 ¾ºÇèÒ ã¹áµèÅлÕÁÕ¼Ùéà»ç¹ÁÐàÃ移ÃÐàÀ·¹Õéà¾ÔèÁ¢Öé¹»ÃÐÁÒ³ 906,000 ÃÒ áÅÐàÊÕªÕÇÔµ 830,000 ÃÒ·ÑèÇâÅ¡ ÁÒ¡à»ç¹Íѹ´ÑºË¡àÁ×èÍà·Õº¡ÑºâäÃéÒÂÍ×è¹ æ áÅÐà»ç¹Íѹ´ÑºÊÒÁàÁ×èÍà·Õº¡ÑºÁÐàÃ秴éÇ¡ѹàͧ[2] ÍѵÃÒ¡ÒÃÍÂÙèÃÍ´ã¹Ãͺ 5 »ÕÍÂÙè·Õè 15%-19% ã¹ÍàÁÃÔ¡Òà˹×Í[3] ¢³Ð·ÕèÀÒÃТͧâäÁÐàÃ秵Ѻ¤è͹¢éÒ§ÊÙ§à»ç¹¾ÔàÈÉ㹨չ «Öè§ã¹¨Õ¹¹Ñé¹ÁÐàÃ秵Ѻà»ç¹âäÃéÒ·Õ辺ä´éºèÍ·ÕèÊØ´à»ç¹Íѹ´Ñº 4 áÅÐà»ç¹ÁÐàÃ秷Õè·ÓãËéÁÕ¼ÙéàÊÕªÕÇÔµÁÒ¡·ÕèÊØ´à»ç¹Íѹ´Ñº 2 ÊèǹÍѵÃÒ¡ÒÃÍÂÙèÃÍ´ã¹Ãͺ 5 »Õ㹨չ¡çÍÂÙè·Õèà¾Õ§ 12.1%[3] ÍѵÃÒÊèǹ 1:0.9 ÃÐËÇèÒ§ÍѵÃÒ¡ÒÃà¡Ô´âä¡ÑºàÊÕªÕÇÔµ¹Ñ鹺觪ÕéÇèÒÁÐàÃ秵Ѻ·Ó¹ÒÂÍÒ¡ÒÃâää´éÂÒ¡[3] «Öè§à»ç¹ÀѤء¤ÒÁµèͪÕÇÔµáÅÐÊØ¢ÀÒ¾¢Í§ªÒǨչ[1][2] â´Â㹪èǧäÁè¡Õè»Õ·Õè¼èÒ¹ÁÒ ¡ÒÃÃÑ¡ÉÒ´éÇÂÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´â´ÂãªéÂÒÂѺÂÑ駡Ò÷ӧҹ·ÕèÍÔÁÁÙ¹àªç¤¾ÍÂµì »ÃÒ¡¯ãËéàËç¹ÍѵÃÒ¡Òõͺʹͧâ´ÂÃÇÁ (ORR) ÍÂÙè·Õè 17%-20% àÁ×èÍãªéà»ç¹ÂÒËÅÑ¡·Õèãªéà»ç¹·Ò§àÅ×Í¡áá áÅÐ 15%-20% àÁ×èÍãªéà»ç¹·Ò§àÅ×Í¡·ÕèÊͧ㹼Ùé»èÇÂÁÐàÃç§à«ÅÅìµÑº[1] ÍÂèÒ§äáç´Õ Âѧ¤§ÁÕ¤ÇÒÁ·éÒ·ÒÂÍÕ¡ÁÒ¡ÁÒ ÃÇÁ¶Ö§¡ÒÃÅØ¡ÅÒÁ¢Í§âäÀÒÂËÅѧ¡ÒÃÃÑ¡ÉÒ áÅÐÊٵ÷ҧàÅ×Í¡à¾×è͵ͺʹͧàÁ×èÍâä¡ÓàÃÔº«éÓ ¡ÒÃÇÔ¨ÑÂÂÒ JWATM204 ¤ÃÑé§ááã¹Á¹ØÉÂì¹Õé ÁÕà»éÒËÁÒÂà¾×èÍ»ÃÐàÁÔ¹¤ÇÒÁ»ÅÍ´ÀÑ ¤ÇÒÁ·¹µèÍÂÒ ¢¹Ò´ÂÒ·Õè·ÓãËéà¡Ô´¤ÇÒÁà»ç¹¾ÔÉ áÅÐÅѡɳзҧàÀÊѪ¨Å¹ÈÒʵÃì¢Í§ÂÒ JWATM204 ã¹ÍÒÊÒÊÁѤÃÇѼÙéãËè·Õèà»ç¹ÁÐàÃç§à«ÅÅìµÑº ¾ÃéÍÁÊÓÃǨķ¸Ôìµè͵éÒ¹à¹×éͧ͡¢Í§ÂÒ JWATM204 㹡ÅØèÁà»éÒËÁÒ ¼Å¡ÒÃÈÖ¡ÉÒÃдѺ¾ÃÕ¤ÅÔ¹Ô¡»ÃÒ¡¯ãËéàËç¹¼ÅÅѾ¸ì¹èÒ¾Í㨠â´ÂáÊ´§ãËéàËç¹ÈÑ¡ÂÀҾ㹡ÒþѲ¹Ò·Ò§¤ÅÔ¹Ô¡¢Í§ÂÒ JWATM204 㹡ÒÃÃÑ¡ÉÒÁÐàÃç§à«ÅÅìµÑº JWATM204 ÁÕÊÑÁ¾ÃäÀÒ¾áÅФÇÒÁ¨Óà¾ÒТͧâÁâ¹â¤Å¹ÍÅá͹µÔºÍ´Õ GPC-3 ã¹ÃдѺÊÙ§ ¾Ñ²¹Ò¢Öé¹·Õèá¾Åµ¿ÍÃìÁ·Õ-à«ÅÅì ARTEMIS(R) ãËéà»ç¹ÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´ÃÑ¡ÉÒâ´Âãªé·Õ-à«ÅÅìºÓºÑ´ «Öè§ÁØè§à»éÒä»·Õè¡ÅÑ»Ô᤹·ÃÕ (GPC-3) â´Â਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì ä´éÃѺ͹ØÒµãËéãªéÊÔ·¸Ô¨Ò¡ÂÙàáéÒ (Eureka) à¾×è;Ѳ¹Ò ¼ÅÔµ áÅШѴ¨Ó˹èÒÂÂÒ JWATM204 㹨չ (ÃÇÁ¨Õ¹á¼è¹´Ô¹ãËè Îèͧ¡§ ÁÒà¡êÒ áÅÐäµéËÇѹ) áÅлÃÐà·ÈÊÁÒªÔ¡ÊÁÒ¤Á»ÃЪҪҵÔáËè§àÍàªÕµÐÇѹÍÍ¡à©Õ§ãµéàÁ×èÍ»Õ 2563 áÅÐä´éâ͹¶èÒ¢éÍÁÙŷҧ෤¹Ô¤áÅкÙóÐʶҹ·ÕèáÅÐÍØ»¡Ã³ìµèÒ§ æ ³ °Ò¹¡ÒüÅÔµà«Õè§äÎé äÇà¡Òà©ÕÂÇ (Shanghai Waigaoqiao) à»ç¹ÍѹáÅéÇàÊÃç¨ à¨ÁÊì ËÅÕè (James Li) ¼ÙéÃèÇÁ¡è͵Ñé§ »Ãиҹ¡ÃÃÁ¡Òà áÅЫÕÍÕâͧ͢਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì ¡ÅèÒÇÇèÒ "ÁÐàÃ秪¹Ô´à»ç¹¡é͹à»ç¹ÊèǹÊÓ¤Ñ㹡ÅÂØ·¸ì¡ÅØèÁ¼ÅÔµÀѳ±ì¢Í§à¨´ÑººÅÔÇ à·ÍÃÒ¾ÔǵԡÊì àÃÒ¹Óá¾Åµ¿ÍÃìÁà·¤â¹âÅÂÕáÅСÒþѲ¹Ò¼ÅÔµÀѳ±ìÁÒãªé â´Â¢³Ð¹Õé¡ÓÅѧ¾Ñ²¹Ò¼ÅÔµÀѳ±ìà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´·ÕèÁÕ¤ÇÒÁ¡éÒÇÅéÓ à¾×èÍÃѺÁ×͡ѺÁÐàÃ秪¹Ô´à»ç¹¡é͹·Õ辺ä´éºèÍÂ㹨չ áÅмÅÑ¡´Ñ¹¼ÅÔµÀѳ±ì·ÕèÍÂÙèÃÐËÇèÒ§¡ÒþѲ¹ÒãËé¶Ö§¢Ñ鹡Ò÷´Åͧ·Ò§¤ÅÔ¹Ô¡" ÍéÒ§ÍÔ§ 1. 肝细胞癌免疫治疗中 国专家共识,2021年, 013;华医学杂志2021 年12月28日第101 卷第48期 2. Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. ACS journals. 2021, 71(3):209-249 3. CSCO原发性肝癌诊疗指 335;,2020年, 中国临床肿瘤学会指 南工作委员会,人民 卫生出版社 à¡ÕèÂǡѺ JWATM204 JWATM204 ÁÕÊÑÁ¾ÃäÀÒ¾áÅФÇÒÁ¨Óà¾ÒТͧâÁâ¹â¤Å¹ÍÅá͹µÔºÍ´Õ GPC-3 ã¹ÃдѺÊÙ§ ¾Ñ²¹Ò¢Öé¹·Õèá¾Åµ¿ÍÃìÁ·Õ-à«ÅÅì ARTEMIS(R) ãËéà»ç¹ÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´ÃÑ¡ÉÒâ´Âãªé·Õ-à«ÅÅìºÓºÑ´ «Öè§ÁØè§à»éÒä»·Õè¡ÅÑ»Ô᤹·ÃÕ (GPC-3) â´Â¡ÅÑ»Ô᤹·ÃÕÍÂÙèã¹µÃСÙÅâ»ÃµÔâÍä¡Å᤹àÂ×èÍËØéÁÀÒÂã¹·ÕèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸ì¡ Ѻ¡ÅÑ»Ô᤹ «Öè§áÊ´§ÍÍ¡ÁÒ¡¼Ô´»¡µÔã¹âäÃéÒÂËÅÒ¡ÅØèÁ ÃÇÁ¶Ö§ÁÐàÃç§à«ÅÅìµÑº áµèäÁèáÊ´§ÍÍ¡ËÃ×ÍáÊ´§ÍÍ¡¹éÍÂÁÒ¡ã¹ÍÇÑÂÇл¡µÔ ÃÇÁ¶Ö§ÍÇÑÂÇеѺ»¡µÔËÃ×͵Ѻá¢ç§ ¡ÅÑ»Ô᤹·ÃÕáÊ´§ÍÍ¡ã¹ 72% ¢Í§¼Ùé»èÇÂÁÐàÃç§à«ÅÅìµÑº[1] â´ÂÁռšèÍÁÐàÃ秼èÒ¹¡Ãкǹ¡Òà Wnt pathway[2] ¡ÅÑ»Ô᤹·ÃÕä´é¡ÅÒÂà»ç¹à»éÒËÁÒÂËÅÑ¡¢Í§ÁÐàÃç§à«ÅÅìµÑº à¾ÃÒÐÁÕ¤ÇÒÁÍè͹äËÇáÅФÇÒÁ¨Óà¾ÒÐÊÙ§ ¢³Ð·Õèá¾Åµ¿ÍÃìÁ·Õà«ÅÅì ARTEMIS(R) «Öè§ÁÕ¡Å䡤Ǻ¤ØÁÀÒÂã¹à«ÅÅì·Õè¤ÅéÒ¡Ѻà«ÅÅìºÓºÑ´áºº TCR-T áÅÐÁÒ¾ÃéÍÁ¤ÇÒÁáÁè¹ÂÓàËÁ×͹¡Ñº¡ÒÃÃÑ¡ÉÒ´éÇ CAR-T ¹Ñé¹ ¤Ò´ÇèÒ¨Ðà¢éÒÁÒªèÇÂÅ´ËÃ×͡ӨѴ¡ÅØèÁÍÒ¡Òèҡ¡ÒÃËÅÑè§ä«âµä¤¹ì (CRS) ·ÕèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸ì¡Ñº¡ÒáÃеØé¹ãËéà¡Ô´·Õà«ÅÅìÁÒ¡à¡Ô¹ä»áÅФÇÒÁà»ç¹¾ÔÉÍ×è¹ æ ·ÕèÊÑÁ¾Ñ¹¸ì¡Ñºä«âµä¤¹ìáÅÐÃéÒÂáç¶Ö§ªÕÇÔµä´é â´ÂâÁàÅ¡ØÅÃèÇÁẺ co-stimulatory º¹¾×é¹¼ÔǢͧ·Õà«ÅÅì ·ÓãËéÊÃéÒ§ÊÑÒ³¡ÃеØé¹·Õà«ÅÅìä´éà¾Õ§¾Í «Ö觪èÇÂÊè§àÊÃÔÁ¡ÒáÃеØé¹·Õà«ÅÅìáÅзÓãËéÄ·¸ÔìµéÒ¹à¹×éͧ͡à¢éÁá¢ç§¢Öé¹ ÍéÒ§ÍÔ§: 1. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125:89-97. 2. Kolluri A and Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front. Oncol. 2019, 9:708. à¡ÕèÂǡѺ਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì ਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì (JW Therapeutics) (HKEX: 2126) à»ç¹ºÃÔÉÑ·à·¤â¹âÅÂÕªÕÇÀÒ¾ÅéÓÊÁÑ·ÕèÁØ觾Ѳ¹Ò ¼ÅÔµ áÅШѴ¨Ó˹èÒÂà·¤â¹âÅÂÕ¡ÒúӺѴ´éÇÂà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ ਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì ¡è͵Ñ駢Öé¹àÁ×èÍ»Õ 2559 â´ÂÁÕ¤ÇÒÁÁØè§ÁÑè¹ã¹¡ÒáéÒÇ¢Öé¹à»ç¹¼Ùé¹Ó¹Çѵ¡ÃÃÁ¡ÒúӺѴ´éÇÂà«ÅÅìÀÙÁÔ¤ØéÁ ¡Ñ¹ ºÃÔÉÑ·ä´éÊÃéÒ§á¾Åµ¿ÍÃìÁÃдѺàÇÔÅ´ì¤ÅÒÊÊÓËÃѺ¡ÒþѲ¹Òà·¤â¹âÅÂÕáÅмÅÔµÀѳ± ì´éÒ¹¡ÒúӺѴ´éÇÂà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ àªè¹à´ÕÂǡѺ¡ÅØèÁ¼ÅÔµÀѳ±ì·ÕèÁÕÈÑ¡ÂÀÒ¾¤Ãͺ¤ÅØÁ·Ñ駡ÅØèÁâäàÅ×Í´·Õèà»ç¹ÁÐ àÃç§áÅÐÁÐàÃ秪¹Ô´à»ç¹¡é͹ ਴ѺºÅÔÇ à·ÍÃÒ¾ÔǵԡÊì ÁØè§ÁÑè¹¹ÓàʹͼÅÔµÀѳ±ìà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´·ÕèÁդسÀÒ¾áÅÐÅéÓ˹éÒ à¾×è͹ӤÇÒÁËÇѧ㹡ÒÃÃÑ¡ÉÒâäãËé¼Ùé»èǪÒǨչáÅзÑèÇâÅ¡ ¾ÃéÍÁÊè§àÊÃÔÁãËéÍصÊÒË¡ÃÃÁà«ÅÅìÀÙÁÔ¤ØéÁ¡Ñ¹ºÓºÑ´¢Í§¨Õ¹àµÔºâµÍÂèÒ§á¢ç§á¡Ãè §áÅÐÁÕÁҵðҹ ´Ù¢éÍÁÙÅà¾ÔèÁàµÔÁä´é·Õ www.jwtherapeutics.com ¢éͤÇÒÁ¤Ò´¡ÒóìÅèǧ˹éÒ ¢éͤÇÒÁ¤Ò´¡ÒóìÅèǧ˹éÒÁÒ¨Ò¡¤ÇÒÁ¤Ò´ËÇѧáÅФÇÒÁàª×èÍ㹻Ѩ¨ØºÑ¹¢Í§½èÒºÃÔ¡ Òà â´ÂÁÕ¤ÇÒÁàÊÕè§ ¤ÇÒÁäÁèá¹è¹Í¹ áÅÐÊÁÁµÔ°Ò¹ÁÒ¡ÁÒ ·ÕèÍÒ¨·ÓãËé¼ÅÅѾ¸ì¨ÃԧᵡµèÒ§ä»ÍÂèÒ§ÁÒ¡¨Ò¡·ÕèÃкØäÇé ¢éͤÇÒÁ¤Ò´¡ÒóìÅèǧ˹éÒ»ÃСͺ´éǤÇÒÁàÊÕè§áÅФÇÒÁäÁèá¹è¹Í¹ÁÒ¡ÁÒ «Öè§ÃÇÁ¶Ö§·ÕèÃкشéÒ¹ÅèÒ§ áÅÐÁÕ¡ÒÃ͸ԺÒÂà¾ÔèÁàµÔÁã¹ÃÒ§ҹ·ÕèºÃÔÉÑ·Â×è¹µè͵ÅÒ´ËØé¹Îèͧ¡§ (HKEX) ºÃÔÉÑ·ãËé¢éÍÁÙŹÕé ³ Çѹ·Õèà¼Âá¾Ãèà·èÒ¹Ñé¹ Â¡àÇé¹ÇèÒ¨ÐÃкØà»ç¹ÍÂèÒ§Í×è¹ áÅÐäÁèÁÕ¢éͼ١¾Ñ¹ã¹¡ÒûÃѺ»Ãا¢éÍÁÙÅ·ÕèÃкØã¹¢èÒÇ·Õèà¼Âá¾ÃèáÅТéÍÁÙÅÍ×è¹ æ ·Õèà¡ÕèÂÇ¢éͧ ËÃ×ÍãËé¤Ó͸ԺÒÂã´ æ ´Ù¢éÍÁÙÅà¾ÔèÁàµÔÁä´é·ÕèàÇçºä«µì¢Í§ºÃÔÉÑ www.jwtherapeutics.com/en/forward-looking-statements/ [1] ALLEMANI C, WEIR HK, CARREIRA H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67countries (CONCORD-2) . Lancet, 2015, 385: 977-1010. [2] TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65: 87-108.
|
|